上海宣泰医药科技股份有限公司关于持股5%以上股东减持计划时间届满暨减持股份结果公告

Group 1 - The major shareholder, Nanjing Qihe Venture Capital Partnership, held 25,798,000 shares of Shanghai Xuantai Pharmaceutical Technology Co., Ltd., accounting for 5.6907% of the total share capital before the reduction plan [1] - The reduction plan announced on July 15, 2025, indicated that the shareholder planned to reduce up to 4,500,000 shares through centralized bidding and up to 2,500,000 shares through block trading between August 5, 2025, and November 4, 2025 [1] - As of November 4, 2025, the shareholder reduced 3,218,000 shares through centralized bidding, representing 0.7098% of the current total share capital [2] Group 2 - The reduction plan was fully implemented as the actual reduction met the minimum reduction quantity disclosed earlier [3] - There were no early terminations of the reduction plan, confirming that the plan proceeded as scheduled [3]